StockMacro
Menu

Cencora

$339.09 +25% in 6 monthsMarket cap $64.7B

COR on XNYS, Wholesale Trade, Cencora, Inc., job postings

Measures activity, not value. Not investment advice.

Twelve-month profit rose 38% to $2.6B while the share price fell 6.3% over the year.

  • GoodFederal contracts reached $4.7B in 12 months, up from $121K

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Jun 2026

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices and global specialty drug logistics (World Courier). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Industry
Wholesale-drugs, proprietaries & druggists' sundries (Wholesale Trade)
Employees
51,000
Website
cencora.com
Listed
NYSE, US
Last results
4 Nov 2026
Next results
expected around 3 Feb 2027 (an estimate: a year ago it reported on 4 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Jun 2026: revenue $84.8B, net income $763.5M.
Quarter to 31 Dec 2021: revenue $59.6B, net income $449.1MQuarter to 31 Dec 2021: revenue $59.6B, net income $449.1MQuarter to 31 Mar 2022: revenue $57.7B, net income $548.0MQuarter to 31 Mar 2022: revenue $57.7B, net income $548.0MQuarter to 30 Jun 2022: revenue $60.1B, net income $407.0MQuarter to 30 Jun 2022: revenue $60.1B, net income $407.0MQuarter to 30 Sep 2022: revenue $61.2B, net income $294.7MQuarter to 30 Sep 2022: revenue $61.2B, net income $294.7MQuarter to 31 Dec 2022: revenue $62.8B, net income $479.7MQuarter to 31 Dec 2022: revenue $62.8B, net income $479.7MQuarter to 31 Mar 2023: revenue $63.5B, net income $435.4MQuarter to 31 Mar 2023: revenue $63.5B, net income $435.4MQuarter to 30 Jun 2023: revenue $66.9B, net income $479.6MQuarter to 30 Jun 2023: revenue $66.9B, net income $479.6MQuarter to 30 Sep 2023: revenue $68.9B, net income $350.6MQuarter to 30 Sep 2023: revenue $68.9B, net income $350.6MQuarter to 31 Dec 2023: revenue $72.3B, net income $601.5MQuarter to 31 Dec 2023: revenue $72.3B, net income $601.5MQuarter to 31 Mar 2024: revenue $68.4B, net income $420.8MQuarter to 31 Mar 2024: revenue $68.4B, net income $420.8MQuarter to 30 Jun 2024: revenue $74.2B, net income $483.5MQuarter to 30 Jun 2024: revenue $74.2B, net income $483.5MQuarter to 30 Sep 2024: revenue $79.1B, net income $3.4MQuarter to 30 Sep 2024: revenue $79.1B, net income $3.4MQuarter to 31 Dec 2024: revenue $81.5B, net income $488.6MQuarter to 31 Dec 2024: revenue $81.5B, net income $488.6MQuarter to 31 Mar 2025: revenue $75.5B, net income $717.9MQuarter to 31 Mar 2025: revenue $75.5B, net income $717.9MQuarter to 30 Jun 2025: revenue $80.7B, net income $687.4MQuarter to 30 Jun 2025: revenue $80.7B, net income $687.4MQuarter to 30 Sep 2025: revenue $83.7B, net income -$339.7MQuarter to 30 Sep 2025: revenue $83.7B, net income -$339.7MQuarter to 31 Dec 2025: revenue $85.9B, net income $559.6MQuarter to 31 Dec 2025: revenue $85.9B, net income $559.6MQuarter to 31 Mar 2026: revenue $78.4B, net income $1.6BQuarter to 31 Mar 2026: revenue $78.4B, net income $1.6BQuarter to 30 Jun 2026: revenue $84.8B, net income $763.5MQuarter to 30 Jun 2026: revenue $84.8B, net income $763.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $85.9B30 Jun 2026
See the numbers
Quarter toRevenueNet income
30 Jun 2026$84.8B$763.5M
31 Mar 2026$78.4B$1.6B
31 Dec 2025$85.9B$559.6M
30 Sep 2025$83.7B-$339.7M
30 Jun 2025$80.7B$687.4M
31 Mar 2025$75.5B$717.9M
31 Dec 2024$81.5B$488.6M
30 Sep 2024$79.1B$3.4M
30 Jun 2024$74.2B$483.5M
31 Mar 2024$68.4B$420.8M
31 Dec 2023$72.3B$601.5M
30 Sep 2023$68.9B$350.6M
30 Jun 2023$66.9B$479.6M
31 Mar 2023$63.5B$435.4M
31 Dec 2022$62.8B$479.7M
30 Sep 2022$61.2B$294.7M
30 Jun 2022$60.1B$407.0M
31 Mar 2022$57.7B$548.0M
31 Dec 2021$59.6B$449.1M
Fundamentals, 12 months to 30 Jun 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $332.8B $316.7B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +5.1% +6.4%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $2.6B $1.9B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $13.47 $9.74
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 4.0% 3.5% 10.3%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 0.9% 0.9% -0.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 0.8% 0.6% -8.5%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 104% 7.9%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $4.1B $1.1B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $2.8B $2.2B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $11.7B $8.2B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $8.9B $6.0B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 3.8 0.59
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $15.99
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 24.7 18.8
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.19 0.30
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 0.22 0.30
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 21.2 1.9
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 0.65% 1.4%

Latest = 12 months to 30 Jun 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
CencoraCOR (this company) $64.7B24.70.19+5.1%0.8%
Cardinal HealthCAH $63.1B34.70.24+10%0.7%
McKessonMCK $123.5B26.30.29+8.2%1.1%
W.W. GraingerGWW $63.5B29.43.3+9.1%11.2%
TE ConnectivityTEL $57.3B17.62.9+15%16.4%
Ferguson EnterprisesFERG $46.5B––––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$5.0M

bought $0, sold $5.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.8%

1,371 13F filers vs 1,321

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

94%

179.2M shares held by 13F filers (30 Sep 2026) of 190.8M outstanding (31 Jul 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.7%

3.2M shares sold short (30 Oct 2026) of 190.8M outstanding (31 Jul 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.6

3.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-20%

3.9M shares sold short in the report before, 3.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

68%

68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

1,033

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+5.1%

$84.8B vs $80.7B (quarter ended 30 Jun 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+23%

$226.0M vs $183.2M (quarter ended 30 Jun 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$4.7B

the 12 months before: $121K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$4.3M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

14

14 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.5×

14 articles in the last 7 days; its usual week has 4.

Price $339.09 on 20 Nov 2026, -6.3% over 12 months (12-month range $252.74 to $374.75)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $11.2M in the last 12 months (the 12 months before: -$374.4M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 8 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $84.8B in the latest quarter, +5.1% on a year earlier.
Capital spending per quarter. Capital spending $226.0M in the latest quarter, +23% on a year earlier.
Institutional holders (13F filers). 1,371 13F filers reported holding it in the latest 13F quarter, +5.9% on a year earlier.
Federal obligations. Federal obligations: $4.7B published in the last 12 months, +7025076% on the 12 months before.
Lobbying spend. Lobbying spend: $4.3M published in the last 12 months, +18% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
25 Sep 20268-K and other filingsDirector or officer change
14 Aug 20268-K and other filingsDirector or officer change
15 Jun 20268-K and other filingsDirector or officer change
29 May 20268-K and other filingsDirector or officer change
17 Mar 20268-K and other filingsDirector or officer change
13 Feb 2026Lobbying filingnew lobbying registration (MONUMENT ADVOCACY)
22 Jan 20268-K and other filingsDirector or officer change
22 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 5,720 vs usual 1,974 (2025-09-22..2025-09-28); 2.4x the same week a year earlier
27 Aug 20258-K and other filingsDirector or officer change
27 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Aug 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 183.2M vs usual 115.3M (2025-06-30); 1.6x the same period a year earlier
21 Jul 2025Lobbying filinglobbying engagement terminated (COLTON STREET GROUP)
17 Jul 2025Lobbying filinglobbying engagement terminated (DGA GROUP GOVERNMENT RELATIONS LLC)
6 Jun 20258-K and other filingsA major agreement ended
2 Jun 2025Lobbying filingnew lobbying registration (COGNITAE)
28 May 20258-K and other filingsDirector or officer change
28 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 May 2025Lobbying filingnew lobbying registration (THE DUBERSTEIN GROUP INC.)
22 Jan 20258-K and other filingsDirector or officer change
22 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jan 2025Sharp changeLobbying spend jump: lobbying spend jump, 1.3M vs usual 685K (2024-12-31); 1.9x the same period a year earlier
2 Jan 20258-K and other filingsCompleted an acquisition or asset sale
20 Oct 2024Lobbying filinglobbying engagement terminated (ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC))
10 Sep 2024Lobbying filinglobbying engagement terminated (MONUMENT STRATEGY & SOLUTIONS)
16 Aug 20248-K and other filingsDirector or officer change
15 Aug 20248-K and other filingsDirector or officer change
15 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 May 20248-K and other filingsDirector or officer change
23 Apr 2024Sharp changeLobbying spend jump: lobbying spend jump, 1.4M vs usual 698K (2024-03-31); 2.0x the same period a year earlier
22 Apr 2024Lobbying filinglobbying engagement terminated (OXFORD STRATEGIES)
7 Apr 2024Lobbying filingnew lobbying registration (INLET STRATEGIES)
27 Mar 2024Lobbying filingnew lobbying registration (MONUMENT STRATEGY & SOLUTIONS)
12 Mar 20248-K and other filingsDirector or officer change
5 Mar 2024Sharp changeShort interest spike: short interest spike, 8.4M vs usual 1.5M (2024-02-15)
27 Feb 20248-K and other filingsMaterial cybersecurity incident
13 Feb 2024Sharp changeShort interest spike: short interest spike, 8.1M vs usual 1.4M (2024-01-31)
30 Jan 2024Sharp changeShort interest spike: short interest spike, 7.9M vs usual 1.3M (2024-01-12)
22 Jan 2024Lobbying filingnew lobbying registration (COLTON STREET GROUP)
16 Jan 2024Sharp changeShort interest spike: short interest spike, 7.3M vs usual 1.3M (2023-12-29)
16 Jan 20248-K and other filingsDirector or officer change
16 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Jan 2024Sharp changeShort interest spike: short interest spike, 8.1M vs usual 1.2M (2023-12-15)
12 Dec 2023Sharp changeShort interest spike: short interest spike, 8.0M vs usual 1.2M (2023-11-30)
28 Nov 2023Sharp changeShort interest spike: short interest spike, 8.2M vs usual 1.1M (2023-11-15)
14 Nov 2023Sharp changeShort interest spike: short interest spike, 6.0M vs usual 1.1M (2023-10-31)
31 Oct 2023Sharp changeShort interest spike: short interest spike, 5.8M vs usual 1.1M (2023-10-13)
17 Oct 2023Sharp changeShort interest spike: short interest spike, 5.8M vs usual 1.1M (2023-09-29)
3 Oct 2023Sharp changeShort interest spike: short interest spike, 4.9M vs usual 1.1M (2023-09-15)
19 Sep 2023Sharp changeShort interest spike: short interest spike, 5.7M vs usual 1.0M (2023-08-31)
31 Aug 2023Lobbying filingnew lobbying registration (BROWNSTEIN HYATT FARBER SCHRECK, LLP)
15 Aug 20238-K and other filingsDirector or officer change
15 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Jan 20238-K and other filingsDirector or officer change
20 Jan 2023Lobbying filinglobbying engagement terminated (FEDERAL HEALTH POLICY STRATEGIES)
16 Nov 20228-K and other filingsDirector or officer change
15 Nov 2022Lobbying filinglobbying engagement terminated (MERCURY PUBLIC AFFAIRS, LLC)
3 Nov 20228-K and other filingsDirector or officer change
27 Sep 20228-K and other filingsDirector or officer change
27 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2022Lobbying filingnew lobbying registration (DGA GROUP GOVERNMENT RELATIONS LLC)
11 Apr 2022Lobbying filingnew lobbying registration (OXFORD STRATEGIES)
1 Apr 20228-K and other filingsDirector or officer change
1 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2022Lobbying filinglobbying engagement terminated (ANWAY LONG GROUP)
Insider net buying (open market)
Month from 1 Nov 2021: -$2.1M published
Month from 1 Dec 2021: -$5.1M published
Month from 1 Jan 2022: -$3.3M published
Month from 1 Feb 2022: -$13.1M published
Month from 1 Mar 2022: -$9.4M published
Month from 1 Apr 2022: -$1.9M published
Month from 1 May 2022: -$903.7M published
Month from 1 Jun 2022: -$1.6M published
Month from 1 Jul 2022: -$1.6M published
Month from 1 Aug 2022: -$1.7M published
Month from 1 Sep 2022: -$1.7M published
Month from 1 Oct 2022: -$1.6M published
Month from 1 Nov 2022: -$2.0B published
Month from 1 Dec 2022: -$1.0B published
Month from 1 Jan 2023: -$1.7M published
Month from 1 Feb 2023: -$2.6M published
Month from 1 Mar 2023: -$1.9M published
Month from 1 Apr 2023: -$1.8M published
Month from 1 May 2023: -$53.1M published
Month from 1 Jun 2023: -$57.0M published
Month from 1 Jul 2023: -$2.0M published
Month from 1 Aug 2023: -$252.0M published
Month from 1 Sep 2023: -$11.6M published
Month from 1 Oct 2023: -$6.6M published
Month from 1 Nov 2023: -$258.5M published
Month from 1 Dec 2023: -$15.9M published
Month from 1 Feb 2024: -$991.9M published
Month from 1 Mar 2024: -$4.2M published
Month from 1 Apr 2024: -$16.1M published
Month from 1 May 2024: -$402.3M published
Month from 1 Jun 2024: -$11.1M published
Month from 1 Jul 2024: -$2.4M published
Month from 1 Aug 2024: -$1.1B published
Month from 1 Sep 2024: -$5.2M published
Month from 1 Oct 2024: -$5.1M published
Month from 1 Nov 2024: -$17.4M published
Month from 1 Dec 2024: -$839K published
Month from 1 Feb 2025: -$315.7M published
Month from 1 Mar 2025: -$11.8M published
Month from 1 Apr 2025: -$5.5M published
Month from 1 May 2025: -$6.6M published
Month from 1 Jun 2025: -$7.8M published
Month from 1 Jul 2025: -$5.7M published
Month from 1 Aug 2025: -$5.7M published
Month from 1 Sep 2025: -$10.6M published
Month from 1 Oct 2025: -$2.3M published
Month from 1 Nov 2025: -$1.9M published
Month from 1 Dec 2025: -$4.9M published
Month from 1 Jan 2026: -$1.8M published
Month from 1 Feb 2026: -$1.8M published
Month from 1 May 2026: $1.1M published
Month from 1 Jun 2026: $1.2M published
Month from 1 Aug 2026: -$3.7M published
Month from 1 Sep 2026: -$732K published
Month from 1 Oct 2026: -$299K published
Month from 1 Nov 2026: -$326K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 13 published
Quarter from 1 Apr 2022: 8 published
Quarter from 1 Jul 2022: 14 published
Quarter from 1 Oct 2022: 9 published
Quarter from 1 Oct 2026: 8 published
Revenue per quarter
Quarter ended 30 Sep 2021: $58.9B, +20% on a year earlier; public on 24 Nov 2021
Quarter ended 31 Dec 2021: $59.6B, +14% on a year earlier; public on 3 Feb 2022
Quarter ended 31 Mar 2022: $57.7B, +17% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $60.1B, +12% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $61.2B, +3.8% on a year earlier; public on 23 Nov 2022
Quarter ended 31 Dec 2022: $62.8B, +5.4% on a year earlier; public on 2 Feb 2023
Quarter ended 31 Mar 2023: $63.5B, +9.9% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $66.9B, +11% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $68.9B, +13% on a year earlier; public on 22 Nov 2023
Quarter ended 31 Dec 2023: $72.3B, +15% on a year earlier; public on 1 Feb 2024
Quarter ended 31 Mar 2024: $68.4B, +7.8% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $74.2B, +11% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $79.1B, +15% on a year earlier; public on 27 Nov 2024
Quarter ended 31 Dec 2024: $81.5B, +13% on a year earlier; public on 6 Feb 2025
Quarter ended 31 Mar 2025: $75.5B, +10% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $80.7B, +8.7% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $83.7B, +5.9% on a year earlier; public on 26 Nov 2025
Quarter ended 31 Dec 2025: $85.9B, +5.5% on a year earlier; public on 5 Feb 2026
Quarter ended 31 Mar 2026: $78.4B, +3.8% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $84.8B, +5.1% on a year earlier; public on 6 Aug 2026
Capital spending per quarter
Quarter ended 30 Sep 2021: $164.8M, +39% on a year earlier; public on 24 Nov 2021
Quarter ended 31 Dec 2021: $79.7M, +22% on a year earlier; public on 3 Feb 2022
Quarter ended 31 Mar 2022: $129.7M, +50% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $113.4M, -6.9% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $173.6M, +5.3% on a year earlier; public on 23 Nov 2022
Quarter ended 31 Dec 2022: $75.7M, -5.0% on a year earlier; public on 2 Feb 2023
Quarter ended 31 Mar 2023: $102.9M, -21% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $104.3M, -8.0% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $175.5M, +1.1% on a year earlier; public on 22 Nov 2023
Quarter ended 31 Dec 2023: $74.2M, -2.0% on a year earlier; public on 1 Feb 2024
Quarter ended 31 Mar 2024: $112.8M, +9.6% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $117.9M, +13% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $182.3M, +3.9% on a year earlier; public on 27 Nov 2024
Quarter ended 31 Dec 2024: $105.9M, +43% on a year earlier; public on 6 Feb 2025
Quarter ended 31 Mar 2025: $129.1M, +14% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $183.2M, +55% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $249.8M, +37% on a year earlier; public on 26 Nov 2025
Quarter ended 31 Dec 2025: $119.4M, +13% on a year earlier; public on 5 Feb 2026
Quarter ended 31 Mar 2026: $165.6M, +28% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $226.0M, +23% on a year earlier; public on 6 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 777; public on 14 Feb 2022
31 Mar 2022 report: 833; public on 16 May 2022
30 Jun 2022 report: 844; public on 15 Aug 2022
30 Sep 2022 report: 810; public on 14 Nov 2022
31 Dec 2022 report: 899; public on 14 Feb 2023
31 Mar 2023 report: 879; public on 15 May 2023
30 Jun 2023 report: 929; public on 14 Aug 2023
30 Sep 2023 report: 894; public on 14 Nov 2023
31 Dec 2023 report: 1,005; public on 14 Feb 2024
31 Mar 2024 report: 1,095; public on 15 May 2024
30 Jun 2024 report: 1,085; public on 14 Aug 2024
30 Sep 2024 report: 1,100; public on 14 Nov 2024
31 Dec 2024 report: 1,162; public on 14 Feb 2025
31 Mar 2025 report: 1,224; public on 15 May 2025
30 Jun 2025 report: 1,289; public on 14 Aug 2025
30 Sep 2025 report: 1,295; public on 14 Nov 2025
31 Dec 2025 report: 1,399; public on 17 Feb 2026
31 Mar 2026 report: 1,400; public on 15 May 2026
30 Jun 2026 report: 1,321; public on 14 Aug 2026
30 Sep 2026 report: 1,371; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $64.1M published
Month from 1 Dec 2021: $304.9M published
Month from 1 Jan 2022: $102.4M published
Month from 1 Feb 2022: $113.3M published
Month from 1 Mar 2022: $166.3M published
Month from 1 Apr 2022: $157.2M published
Month from 1 May 2022: $159.0M published
Month from 1 Jun 2022: $165.4M published
Month from 1 Jul 2022: $157.5M published
Month from 1 Aug 2022: $165.6M published
Month from 1 Sep 2022: $136.9M published
Month from 1 Oct 2022: $70.6M published
Month from 1 Nov 2022: $92.2M published
Month from 1 Dec 2022: $142.1M published
Month from 1 Jan 2023: $47.6M published
Month from 1 Feb 2023: $60.5M published
Month from 1 Mar 2023: $109.0M published
Month from 1 Apr 2023: $194.8M published
Month from 1 May 2023: $176.0M published
Month from 1 Jun 2023: $222.2M published
Month from 1 Jul 2023: $165.7M published
Month from 1 Aug 2023: $245.7M published
Month from 1 Sep 2023: $181.9M published
Month from 1 Oct 2023: $190.7M published
Month from 1 Nov 2023: $281.6M published
Month from 1 Dec 2023: $249.6M published
Month from 1 Jan 2024: $156.9M published
Month from 1 Feb 2024: $154.0M published
Month from 1 Mar 2024: $267.0M published
Month from 1 Apr 2024: $195.8M published
Month from 1 May 2024: $296.4M published
Month from 1 Jun 2024: $264.3M published
Month from 1 Jul 2024: $291.4M published
Month from 1 Aug 2024: $107.8M published
Month from 1 Oct 2024: $18K published
Month from 1 Nov 2024: $18K published
Month from 1 Dec 2024: $11K published
Month from 1 Jan 2025: $10K published
Month from 1 Feb 2025: $12K published
Month from 1 Mar 2025: $12K published
Month from 1 May 2025: $22K published
Month from 1 Jul 2025: -$241 published
Month from 1 Apr 2026: $553.5M published
Month from 1 May 2026: $741.9M published
Month from 1 Jun 2026: $692.0M published
Month from 1 Jul 2026: $728.0M published
Month from 1 Aug 2026: $682.6M published
Month from 1 Sep 2026: $749.3M published
Month from 1 Oct 2026: $543.0M published
Month from 1 Nov 2026: $1.2M published
Lobbying spend
Quarter from 1 Jan 2022: $800K published
Quarter from 1 Apr 2022: $1.1M published
Quarter from 1 Jul 2022: $1.6M published
Quarter from 1 Jan 2023: $645K published
Quarter from 1 Apr 2023: $700K published
Quarter from 1 Jul 2023: $635K published
Quarter from 1 Oct 2023: $595K published
Quarter from 1 Jan 2024: $695K published
Quarter from 1 Apr 2024: $1.4M published
Quarter from 1 Jul 2024: $1.5M published
Quarter from 1 Jan 2025: $1.3M published
Quarter from 1 Apr 2025: $620K published
Quarter from 1 Jul 2025: $885K published
Quarter from 1 Oct 2025: $795K published
Quarter from 1 Jan 2026: $2.0M published
Quarter from 1 Apr 2026: $1.2M published
Quarter from 1 Jul 2026: $570K published
Quarter from 1 Oct 2026: $466K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is workers named in WARN notices at 72 (31 Dec 2012), 44% below its normal reading of 128.
  • Insider net buying (open market): Insiders sold a net $11.2M in the last 12 months (the 12 months before: -$374.4M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 8 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $84.8B in the latest quarter, +5.1% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 5 sales, $5.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
3 Nov 2026Lazarus KrikorianSVP & Chief Accounting OfficerSellplanned in advance (10b5-1)986$330.96$326KForm 4
5 Oct 2026Lazarus KrikorianSVP & Chief Accounting OfficerSellplanned in advance (10b5-1)986$303.18$299KForm 4
17 Sep 2026Lon R GreenbergDirectorSell1,280$321.30$411KForm 4
2 Sep 2026Lazarus KrikorianSVP & Chief Accounting OfficerSellplanned in advance (10b5-1)985$325.97$321KForm 4
25 Aug 2026Elizabeth S CampbellExecutive Vice PresidentSell11,300$324.12$3.7MForm 4
24 Jun 2026Lauren M TylerDirectorBuy550$270.23$149KForm 4
22 Jun 2026Dermot Mark DurcanDirectorBuy4,000$274.19$1.1MForm 4
28 May 2026Dermot Mark DurcanDirectorBuy4,000$266.26$1.1MForm 4

1,371 institutions reported shares at the end of Q3 2026, 94% of the shares outstanding; 127 opened a position, 97 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.18.2M9.55%$5.5B+15K+0.1%
Vanguard Capital Management LLC12.2M6.38%$3.7B-207K-1.7%
Vanguard Portfolio Management LLC9.4M4.93%$2.8B-204K-2.1%
State Street Corp9.2M4.82%$2.8B-71K-0.8%
Wellington Management Group LLP8.5M4.45%$2.6B+3.9M+86%
T. Rowe Price Investment Management, Inc.6.6M3.48%-762K-10%
JPMorgan Chase & Co5.9M3.07%$1.8B-86K-1.4%
T. Rowe Price Associates Inc5.7M2.98%-1.5M-20%
Geode Capital Management, LLC5.4M2.85%$1.6B-26K-0.5%
Boston Partners5.2M2.75%$1.6B+379K+7.8%

Federal contracts

All 492 federal contracts

371 new awards in 12 months, $750.5M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
23 Jul 2026Department of DefenseDefense Logistics Agency$1.2M4572463477!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
23 Jul 2026Department of DefenseDefense Logistics Agency$1.4M4572463481!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
22 Jul 2026Department of DefenseDefense Logistics Agency$3.0M4572452443!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
22 Jul 2026Department of DefenseDefense Logistics Agency$1.3M4572452434!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
22 Jul 2026Department of DefenseDefense Logistics Agency$4.3M4572452438!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
22 Jul 2026Department of DefenseDefense Logistics Agency$4.3M4572452453!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
22 Jul 2026Department of DefenseDefense Logistics Agency$2.9M4572452462!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending
20 Jul 2026Department of DefenseDefense Logistics Agency$1.5M4572443378!PV PHARM BRANCH, VENDOR, CAGE 0U9U0USAspending

Company events

All 80 company events

In 12 months: 6 director or officer changes, 3 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
25 Sep 2026Director or officer change8-K
14 Aug 2026Director or officer change8-K
5 Aug 2026Signed a major agreementSame filing: took on new debt8-K
15 Jun 2026Director or officer change8-K
29 May 2026Director or officer change8-K
17 Mar 2026Director or officer change8-K
13 Feb 2026Signed a major agreementSame filing: took on new debt8-K
22 Jan 2026Director or officer change8-K

1,033 open postings; careers site tracked since 21 Nov 2026. Most in Supply chain & procurement 33%, Operations & administration 11%, Finance & accounting 6%, Sales & business development 4%.

PostedJobLocation
20 Nov 2026Caseworker, Patient Support & ServicesOperations & administrationRemote, Alberta, Canada; Remote, British Columbia, Canada
20 Nov 2026Tech II - Ambulatory PharmacyWyomissing, Pennsylvania, United States of America; Reading, Pennsylvania, United States of America
20 Nov 2026Principal Program Manager, IT ComplianceProgram & project managementPhiladelphia, Pennsylvania, United States of America; Remote, Texas, United States of America
20 Nov 2026Senior Warehouse Associate | DaysSupply chain & procurementMansfield, Massachusetts, United States of America
20 Nov 2026Senior Project Manager, IT AnalyticsProgram & project managementPhiladelphia, Pennsylvania, United States of America; Remote, Texas, United States of America
20 Nov 2026Staff Pharmacist Full-Time FloatReading, Pennsylvania, United States of America
20 Nov 2026Warehouse OperativeSupply chain & procurementExeter, United Kingdom
20 Nov 2026Senior Engineer, IAM Platform EngineeringSRE, DevOps & infrastructurePune, India

Reported lobbying spend: $466K in Q3 2026, $570K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jan 2026NewMonument Advocacyfor CencoraHR 405-EMSSA; Act; H.R. 3164, S. 2464, Equitable Community Access to Pharmacists Act; MFN Drug pricing issues; 2026 Medicare Physician FeeSchedule Proposed Rule.Health issuesFiling
30 Jun 2025EndedColton Street Groupfor Harbinger Strategies, LLC On Behalf Of Cencora, Inc.Issues related to Healthcare Reform.; Business tax issues.Health issues, TaxationFiling
2 Jun 2025NewCognitaefor CencoreNDAA AppropriationsDefenseFiling
15 Apr 2025NewThe Duberstein Group Inc.for Cencora, Inc.Issues related to Healthcare Reform; Issues related to Tax ReformHealth issues, Medicare/Medicaid, Pharmacy, TaxationFiling
1 Apr 2025EndedDga Group Government Relations LLCfor Cencora Inc. (Formerly Known As Amerisourcebergen)Not statedFiling
1 Sep 2024EndedMonument Strategy & Solutionsfor CencoreAppropriationsDefenseFiling
15 Jul 2024EndedRoberti Global (F/K/A Roberti White, LLC)for Amerisourcebergen CorporationNot statedFiling
4 Mar 2024NewMonument Strategy & Solutionsfor CencoreNdAA and Defense AppropriationsDefenseFiling

Layoff notices

All 2 layoff notices

No notice in 12 months; the latest is dated 1 Jan 2013. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Jan 2013AmerisourceBergen Drug CorporationThorofare, NJ725 Apr 2013Notice
1 May 2006AMERISOURCEBERGENPINE BROOK, NJ12822 Jul 2006Notice

The 5 newest of 253 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 23 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2S91 ($1.2M) (dated 23 Jul 2026)

  2. 23 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F23Q4 ($1.4M) (dated 23 Jul 2026)

  3. 22 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FB0DU ($3.0M) (dated 22 Jul 2026)

  4. 22 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FAR3T ($1.3M) (dated 22 Jul 2026)

  5. 22 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2S89 ($4.3M) (dated 22 Jul 2026)

  6. 22 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F23Q1 ($4.3M) (dated 22 Jul 2026)

  7. 22 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JNP ($2.9M) (dated 22 Jul 2026)

  8. 20 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FAEQ4 ($1.5M) (dated 20 Jul 2026)

  9. 17 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F23A5 ($1.3M) (dated 17 Jul 2026)

  10. 17 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JHP ($1.1M) (dated 17 Jul 2026)

  11. 16 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FA9XX ($1.8M) (dated 16 Jul 2026)

  12. 16 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2R39 ($2.9M) (dated 16 Jul 2026)

  13. 16 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F23A2 ($2.4M) (dated 16 Jul 2026)

  14. 16 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JHL ($1.9M) (dated 16 Jul 2026)

  15. 14 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FA9XL ($2.3M) (dated 14 Jul 2026)

  16. 14 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2R29 ($3.3M) (dated 14 Jul 2026)

  17. 14 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F22Z4 ($3.5M) (dated 14 Jul 2026)

  18. 14 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JHE ($2.3M) (dated 14 Jul 2026)

  19. 13 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FAEM9 ($1.5M) (dated 13 Jul 2026)

  20. 10 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FA9RU ($1.1M) (dated 10 Jul 2026)

  21. 10 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2P87 ($2.4M) (dated 10 Jul 2026)

  22. 10 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F22M2 ($1.5M) (dated 10 Jul 2026)

  23. 10 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JCG ($1.2M) (dated 10 Jul 2026)

  24. 9 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FAQ6B ($1.2M) (dated 9 Jul 2026)

  25. 9 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F22M0 ($1.6M) (dated 9 Jul 2026)

  26. 9 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JCE ($1.6M) (dated 9 Jul 2026)

  27. 8 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FA9RQ ($1.7M) (dated 8 Jul 2026)

  28. 8 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2P81 ($2.1M) (dated 8 Jul 2026)

  29. 8 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F22L7 ($1.9M) (dated 8 Jul 2026)

  30. 8 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JCC ($1.3M) (dated 8 Jul 2026)

  31. 7 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FA9RM ($1.6M) (dated 7 Jul 2026)

  32. 7 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2P79 ($2.5M) (dated 7 Jul 2026)

  33. 7 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F22L5 ($2.4M) (dated 7 Jul 2026)

  34. 7 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0JCA ($2.0M) (dated 7 Jul 2026)

  35. 3 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FAQ2X ($1.7M) (dated 3 Jul 2026)

  36. 3 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826FA9LF ($2.4M) (dated 3 Jul 2026)

  37. 3 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2N49 ($1.0M) (dated 3 Jul 2026)

  38. 3 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F2N48 ($3.9M) (dated 3 Jul 2026)

  39. 3 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F21X8 ($4.2M) (dated 3 Jul 2026)

  40. 3 Oct 2026Government contracts record

    AMERISOURCEBERGEN DRUG CORP: new Department of Defense contract SPE2D826F0HYB ($3.0M) (dated 3 Jul 2026)

Showing the newest 40 of 150 entries; narrow the window or the kind of data to see older ones.

Not listed: 505 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001140859
Ticker
COR
Domain
cencora.com
Employer name
AmerisourceBergen Corporation, amerisourcebergen drug, amerisourcebergen services, amerisourcebergen specialty group (4 unverified)
Hq location
PA|CONSHOHOCKEN|19428 (1 unverified)
Lobbying client
amerisource bergen, amerisourcebergen, amerisourcebergen corporation formerly amerisourcebergen specialty group, cencora and 6 more
Name
AB Singapore Investments Pte. Ltd, AH UK Holdco 1 Limited, AMERISOURCE BERGEN CORP, AmerisourceBergen Corporation and 20 more
Uei
NWEGNLYTBDW4
Wikidata
Q470156
Wikipedia
Cencora
  • DOL H-1B labor condition applications and PERM certifications446 data points4 Nov 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)70 records, 243 data points5 Jan 2005 to 30 Sep 2026
  • SEC Form 13F institutional holdings5 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)217 records4 Feb 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1127 data points30 Sep 2006 to 31 Jul 2026
  • SEC Form 4 insider transactions336 records, 1144 data points3 Mar 2016 to 3 Nov 2026
  • FINRA short interest (twice monthly)519 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3338 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards492 records, 18453 data points1 Oct 2007 to 17 Nov 2026
  • WARN layoff notices (state labor agencies)2 records, 6 data points1 May 2006 to 1 Jan 2013
  • Wikipedia pageviews1180 data points30 Aug 2023 to 21 Nov 2026